44P Long-term follow-up of selinexor (SEL) maintenance treatment in patients with TP53 wild type (wt) advanced/recurrent (A/R) endometrial cancer (EC): Intermediate endpoints by mismatch repair (MMR) status in the ENGOT-EN5/GOG-3055/SIENDO study | Publicación